Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 260.00
Bid: 220.00
Ask: 300.00
Change: 0.00 (0.00%)
Spread: 80.00 (36.364%)
Open: 260.00
High: 260.00
Low: 260.00
Prev. Close: 260.00
SPSC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Financial Officer

30 May 2023 07:00

RNS Number : 8942A
Spectra Systems Corporation
30 May 2023
 

Spectra Systems Corporation

30 May, 2023

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

Spectra Systems Corporation

Appointment of Chief Financial Officer

Spectra Systems Corporation, a leader in machine-readable high speed banknote authentication, brand protection technologies and gaming security software is delighted to announce that it has agreed to appoint Edward Spies (age 56) as Chief Financial Officer, upon the completion of due diligence by its nominated adviser.

Edward Spies is an experienced accounting and finance professional with over 25 years of expertise in financial planning and analysis, mergers and acquisitions, and business process improvement. He brings decades of experience in the technology industry, having started his career at PricewaterhouseCoopers, and worked in various finance leadership roles since then. Recently, he served as CFO of Mearthane Products Corporation, a polymer component manufacturer. Prior to that, he held positions as a Corporate Controller and VP of Finance at several VC and PE backed portfolio companies. He also helped build the CFO services practice for CFGI, and embarked on a successful consulting career providing accounting and finance support for start-up and publicly traded companies.

Mr. Spies has considerable expertise in manufacturing, cost and profit margin analysis, and financial management. He earned his CPA earlier in his career and holds a bachelor's degree from Clarkson University and an MBA/MS in Accounting from Northeastern University.

Edward Spies has confirmed that there is no further information to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

Dr. Nabil Lawandy, CEO of Spectra Systems, stated: "I am delighted to welcome Ed to Spectra Systems and believe that his breadth of experience, particularly in technology companies as well as mergers and acquisitions, will be of great value to the company in its next phase of growth."

The person responsible for arranging the release of this announcement on behalf of the Company is Dr. Nabil Lawandy, Chief Executive of the Company.

Enquiries:

 

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer

 

Tel: +1 (0)401 274 4700

WH Ireland Limited (Nominated Adviser and Broker)

Chris Fielding (Deputy Head of Corporate Finance)

Andrew de Andrade (Executive, Corporate Finance) 

 

Allenby Capital Limited (Joint Broker)

Nick Naylor/James Reeve (Corporate Finance)

Amrit Nahal (Sales and Corporate Broking) 

Tel: +44 (0)20 7220 1650

Tel: +44 (0)20 3328 5665

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEDFWUEDSEFI
Date   Source Headline
14th Jun 20217:00 amRNSAnnual General Meeting Update
17th May 20215:12 pmRNSShare Buy-Back
7th May 20214:49 pmRNSShare Buy-Back
6th May 20212:58 pmRNSShare Buy-Back
4th May 20215:51 pmRNSPosting of Annual Report and Accounts, AGM Notice
26th Apr 20211:45 pmRNSExercise of Options
22nd Apr 20217:00 amRNSNew Lottery Contracts
21st Apr 20217:00 amRNSEnhanced sensor capability contract
19th Apr 20211:46 pmRNSExercise of Options
8th Apr 20217:00 amRNSAllowance of Banknote Disinfection Patent
1st Apr 20213:29 pmRNSExercise of Options and Director/PDMR Shareholding
22nd Mar 20217:35 amRNSAudited Results for the 12 months ended 31 Dec 20
10th Feb 20217:00 amRNSExercise of Options
9th Feb 20212:11 pmRNSAppointment of Director
2nd Feb 20217:00 amRNSSecond phase of contract for sensor development
1st Feb 20213:33 pmRNSExercise of Options
20th Jan 20217:00 amRNSExercise of Options and Director/PDMR Shareholding
5th Jan 20214:02 pmRNSDirectorate
5th Jan 20217:00 amRNSShare Buy-Back
14th Dec 20207:01 amRNSTwo Lottery Renewals
14th Dec 20207:00 amRNSAcquisition of interest - Solaris BioSciences, Inc
21st Oct 20209:06 amRNSSecond Price Monitoring Extn
21st Oct 20209:01 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSContract with a Central Bank
14th Oct 20205:27 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSRemoval of Regulation S Restrictions
11th Sep 20204:34 pmRNSExercise of Options and Director/PDMR Shareholding
10th Sep 20207:00 amRNSExercise of Options and Director/PDMR Shareholding
7th Sep 20207:00 amRNSInterim Results for the Six Months 30 June 20
25th Aug 20204:11 pmRNSHolding(s) in Company
15th Jul 20206:25 pmRNSDirector Dealings
9th Jul 20207:00 amRNSContract with a Major Central Bank
26th Jun 20207:00 amRNSShare Buy-Back
25th Jun 20207:00 amRNSShare Buy-Back and Removal of Reg S Restrictions
16th Jun 20203:23 pmRNSShare Buy-Back
10th Jun 20207:00 amRNSAsian Central Bank Contract Update
26th May 20207:00 amRNSDirector Dealings
15th May 20205:24 pmRNSExercise of Options and Removal of Regulation S
30th Apr 20208:51 amRNSPosting of Annual Report and Accounts
3rd Apr 20204:56 pmRNSShare Buy-Back and Removal of Reg S Restrictions
23rd Mar 202012:37 pmRNSAudited Results
16th Mar 20201:59 pmRNSHolding(s) in Company
9th Mar 20204:41 pmRNSPrice Monitoring Extension
21st Feb 20207:00 amRNSShare Buy-Back
11th Nov 20193:30 pmRNSHolding(s) in Company
30th Oct 20191:39 pmRNSHolding(s) in Company
16th Oct 20197:00 amRNSHolding(s) in Company
25th Sep 20192:59 pmRNSHolding(s) in Company
24th Sep 20197:00 amRNSInterim Results
17th Sep 20197:00 amRNSFunding Approval - G7 Central Bank

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.